Obviously none of this would be going on if PER was trading above 1.4 cents cash backing, but let's humour ourselves. Gennadi & Co think aTL1102 phase 2 results are wrong and drug still has heaps of value in DMD. Garner has new drugs he likes, obviously small up front cash costs , back loaded payments to vendor if successful, potential to be starting humans trials within 12 months. PVL wants to use PER as an investment vehicle dedicated to the bio-tech space? I still think Garner has potential to add more value. Can Garner find someone to invest $1 million on his vision ahead of the votes ?, otherwise we could be stuck with fleas
PER Price at posting:
1.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)